Breaking Biotech

047 - Sarepta Receives CRL for Golodirsen! IOVA impresses in solid tumors.


Listen Later

In this video, I talk about Sarepta and their issues regarding the CRL received for Golodirsen. I also take a close look at Iovance Biotherapeutics and their tumor infiltrating lymphocyte cell therapy for cancer treatment. this is not investment advice breakingbiotech #SRPT #IOVA www.breakingbiotech.com Support Breaking Biotech by donating to the tip jar: https://tips.pinecast.com/jar/breaking-biotech
...more
View all episodesView all episodes
Download on the App Store

Breaking BiotechBy Matthew Lepoire

  • 4.9
  • 4.9
  • 4.9
  • 4.9
  • 4.9

4.9

24 ratings